Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283629 · ClinicalTrials.gov registry record · NA
nCCR for Chemotherapy Related Cognitive Impairment Randomized Study
A NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment, sponsored by University of Massachusetts, Worcester.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05283629: Active NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment, sponsored by University of Massachusetts, Worcester.
NCT05283629 is a NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment that is active but no longer recruiting, run by University of Massachusetts, Worcester. The registered enrollment target is 50 participants, below the 87-participant average among 4 other Chemo-brain trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283629, a NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment, is active but no longer recruiting, sponsored by University of Massachusetts, Worcester.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).
Primary Outcome
Paired samples t-tests will be used to assess FACT-Cog PCI Scores. We hypothesize that nCCR treatment will improve FACT-Cog scores in breast cancer patients with persistent CRCI over 6 weeks of treatment compared to the education control group. The primary measure used to assess subjective cognitive performance was the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale and evaluates memory, concentration, mental acuity, verbal fluency, functional interference, and multi
Conditions Studied
Interventions
- BEHAVIORAL Neuroplasticity-based Computerized Cognitive Remediation
- BEHAVIORAL Active Control Condition
Study Locations (1)
Massachusetts
- UMass Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2030-03-01 |
| Phase | NA |
What the registry record for NCT05283629 still lists
NCT05283629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 87-participant average among 4 other Chemo-brain trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Chemo-brain appearing as the primary indexed condition, and to 2 interventions - of which Neuroplasticity-based Computerized Cognitive Remediation is the first listed.
NCT05283629 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05283629 about?
NCT05283629 is a clinical study titled "nCCR for Chemotherapy Related Cognitive Impairment Randomized Study". The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).
What is the current status of trial NCT05283629?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-08-01. Estimated completion is 2030-03-01.
What conditions does trial NCT05283629 study?
This clinical trial studies the following conditions: Chemo-brain, Chemotherapy-Related Cognitive Impairment.
What interventions are being tested in trial NCT05283629?
The interventions under investigation include: Neuroplasticity-based Computerized Cognitive Remediation (BEHAVIORAL), Active Control Condition (BEHAVIORAL).
Who is sponsoring clinical trial NCT05283629?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283629 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemo-brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improve Cancer-related Cognitive Impairment
RECRUITING · NA
-
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
RECRUITING · NA
-
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
RECRUITING
-
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI